Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications

  • Carrillo-Reixach, Juan|||0000-0002-8538-8264
  • Torrens, Laura
  • Simón-Coma, Marina
  • Royo, Laura|||0000-0001-5770-2001
  • Domingo-Sàbat, Montse|||0000-0001-6687-3259
  • Abril-Fornaguera, Jordi|||0000-0002-5871-4052
  • Akers, Nicholas
  • Sala Llinas, Margarita|||0000-0003-4879-1780
  • Ragull, Sonia
  • Arnal, Magdalena|||0000-0001-8647-9232
  • Villalmanzo, Núria
  • Cairo, Stefano
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Kappler, Roland
  • Garrido-Pontnou, Marta|||0000-0002-7762-7085
  • Guerra Pastrian, Laura|||0000-0002-8478-8522
  • Sábado, Constantino|||0000-0003-3956-5466
  • Guillén, Gabriela|||0000-0001-5632-2672
  • Mallo, Maria del Mar|||0000-0001-7741-498X
  • Piñeyro, David|||0000-0001-5633-3339
  • Vázquez-Vitali, María
  • Kuchuk, Olga
  • Mateos, María Elena
  • Ramírez, Gema
  • López Santamaría, Manuel
  • Mozo, Yasmina
  • Soriano, Aroa|||0000-0001-9659-1471
  • Grotzer, Michael
  • Branchereau, Sophie
  • García de Andoin, Nagore
  • López-Ibor, Blanca
  • López-Almaraz, Ricardo
  • Salinas, José Antonio
  • Torres, Bárbara
  • Hernández, Francisco
  • Uriz, José Javier
  • Fabre, Monique
  • Blanco, Julià|||0000-0002-2225-0217
  • Paris, Claudia
  • Bajčiová, Viera
  • Laureys, Geneviève
  • Masnou, Helena|||0000-0003-0632-1393
  • Clos, Ariadna|||0000-0002-6414-2097
  • Beléndez, Cristina|||0000-0002-6019-6557
  • Guettier, Catherine
  • Sumoy, Lauro|||0000-0003-0005-4618
  • Planas, Ramón
  • Jordà, Mireia|||0000-0003-3709-1850
  • Nonell, Lara|||0000-0002-8538-8213
  • Czauderna, Piotr
  • Morland, Bruce
  • Sia, Daniela|||0000-0002-9000-611X
  • Losic, Bojan
  • Buendia, Marie Annick
  • Sarrias, Maria-Rosa|||0000-0001-6929-8069
  • Llovet, Josep M.|||0000-0003-0547-2667
  • Armengol, Carolina|||0000-0002-4690-4027
Background & Aims: Hepatoblastoma (HB) is a rare disease. Nevertheless, it is the predominant pediatric liver cancer, with limited therapeutic options for patients with aggressive tumors. Herein, we aimed to uncover the mechanisms of HB pathobiology and to identify new biomarkers and therapeutic targets in a move towards precision medicine for patients with advanced HB. Methods: We performed a comprehensive genomic, transcriptomic and epigenomic characterization of 159 clinically annotated samples from 113 patients with HB, using high-throughput technologies. Results: We discovered a widespread epigenetic footprint of HB that includes hyperediting of the tumor suppressor BLCAP concomitant with a genome-wide dysregulation of RNA editing and the overexpression of mainly non-coding genes of the oncogenic 14q32 DLK1-DIO3 locus. By unsupervised analysis, we identified 2 epigenomic clusters (Epi-CA, Epi-CB) with distinct degrees of DNA hypomethylation and CpG island hypermethylation that are associated with the C1/C2/C2B transcriptomic subtypes. Based on these findings, we defined the first molecular risk stratification of HB (MRS-HB), which encompasses 3 main prognostic categories and improves the current clinical risk stratification approach. The MRS-3 category (28%), defined by strong 14q32 locus expression and Epi-CB methylation features, was characterized by CTNNB1 and NFE2L2 mutations, a progenitor-like phenotype and clinical aggressiveness. Finally, we identified choline kinase alpha as a promising therapeutic target for intermediate and high-risk HBs, as its inhibition in HB cell lines and patient-derived xenografts strongly abrogated tumor growth. Conclusions: These findings provide a detailed insight into the molecular features of HB and could be used to improve current clinical stratification approaches and to develop treatments for patients with HB. Lay summary: Hepatoblastoma is a rare childhood liver cancer that has been understudied. We have used cutting-edge technologies to expand our molecular knowledge of this cancer. Our biological findings can be used to improve clinical management and pave the way for the development of novel therapies for this cancer.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

MacroH2As regulate enhancer-promoter contacts affecting enhancer activity and sensitivity to inflammatory cytokines

  • Corujo, David|||0000-0001-7930-0935
  • Malinverni, Roberto|||0000-0002-0113-3417
  • Carrillo-Reixach, Juan|||0000-0002-8538-8264
  • Meers, Oliver|||0000-0001-9532-7767
  • Garcia-Jaraquemada, Arce|||0000-0001-6603-2003
  • Le Pannérer, Marguerite Marie|||0000-0002-5779-8805
  • Valero, Vanesa
  • Pérez, Ainoha
  • Del Río-Álvarez, Álvaro|||0000-0003-2338-0782
  • Royo, Laura|||0000-0001-5770-2001
  • Pérez-González, Beatriz|||0000-0001-9849-5176
  • Raurell Vila, Helena|||0000-0003-1196-836X
  • Acemel, Rafael D.|||0000-0003-4120-0140
  • Santos-Pereira, José M.|||0000-0003-3949-0644
  • Garrido-Pontnou, Marta|||0000-0002-7762-7085
  • Gómez-Skarmeta, José Luís|||0000-0001-5125-4332
  • Pasquali, Lorenzo|||0000-0003-2423-1826
  • Manyé, Josep|||0000-0002-3121-8016
  • Armengol, Carolina|||0000-0002-4690-4027
  • Buschbeck, Marcus|||0000-0002-3218-4567
MacroH2A histone variants have a function in gene regulation that is poorly understood at the molecular level. We report that macroH2A1.2 and macroH2A2 modulate the transcriptional ground state of cancer cells and how they respond to inflammatory cytokines. Removal of macroH2A1.2 and macroH2A2 in hepatoblastoma cells affects the contact frequency of promoters and distal enhancers coinciding with changes in enhancer activity or preceding them in response to the cytokine tumor necrosis factor alpha. Although macroH2As regulate genes in both directions, they globally facilitate the nuclear factor κB (NF-κB)-mediated response. In contrast, macroH2As suppress the response to the pro-inflammatory cytokine interferon gamma. MacroH2A2 has a stronger contribution to gene repression than macroH2A1.2. Taken together, our results suggest that macroH2As have a role in regulating the response of cancer cells to inflammatory signals on the level of chromatin structure. This is likely relevant for the interaction of cancer cells with immune cells of their microenvironment.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Mycobacterium manresensis induces trained immunity in vitro

  • Homdedeu, Miquel de|||0000-0002-2865-1740
  • Sanchez-Moral, Lidia|||0000-0002-3795-8015
  • Violán, Concepció|||0000-0003-3309-5360
  • Ràfols, Neus
  • Ouchi, Dan|||0000-0002-8630-152X
  • Martín, Berta
  • Peinado, Miguel A.
  • Rodriguez-Cortes, Alheli|||0000-0003-3617-0119
  • Arch Sisquella, Marta|||0000-0002-2120-1667
  • Perez-Zsolt, Daniel|||0000-0003-4192-7622
  • Muñoz-Basagoiti, Jordana|||0000-0002-0384-5928
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
  • Salvador, Betlem
  • Matllo, Joan
  • López-Serrano, Sergi|||0000-0002-0968-7713
  • Segalés Coma, Joaquim|||0000-0002-1539-7261
  • Vilaplana Massaguer, Cristina|||0000-0002-2808-7270
  • Torán-Monserrat, Pere|||0000-0002-9865-7427
  • Morros, Rosa|||0000-0001-6752-8748
  • Monfà, Ramon|||0000-0002-1324-3971
  • Sarrias, Maria-Rosa|||0000-0001-6929-8069
  • Cardona, Pere-Joan|||0000-0001-5623-7873
The COVID-19 pandemic posed a global health crisis, with new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants weakening vaccine-driven protection. Trained immunity could help tackle COVID-19 disease. Our objective was to analyze whether heat-killed Mycobacterium manresensis (hkMm), an environmental mycobacterium, induces trained immunity and confers protection against SARS-CoV-2 infection. To this end, THP-1 cells and primary monocytes were trained with hkMm. The increased secretion of tumor necrosis factor alpha (TNF-α), interleukin (IL)-6, IL-1β, and IL-10, metabolic activity, and changes in epigenetic marks suggested hkMm-induced trained immunity in vitro. Healthcare workers at risk of SARS-CoV-2 infection were enrolled into the MANRECOVID19 clinical trial (NCT04452773) and were administered Nyaditum resae (NR, containing hkMm) or placebo. No significant differences in monocyte inflammatory responses or the incidence of SARS-CoV-2 infection were found between the groups, although NR modified the profile of circulating immune cell populations. Our results show that M. manresensis induces trained immunity in vitro but not in vivo when orally administered as NR daily for 14 days. Biological sciences; Molecular biology; Immunology; Microbiology.